Comment from Empower Clinic Services
AnonymousSupportBusiness
Summary: Empower Pharmacy supports the FDA's goal of promoting clear, risk-based responses to Form 483 observations but requests specific clarifications regarding the guidance's applicability to 503A compounding facilities. They advocate for clearer communication pathways regarding inspection outcomes, more flexible response formats, and defined timelines for post-inspection status updates.
Empower Pharmacy respectfully submits the attached comment letter in response to FDA’s draft guidance, Responding to FDA Form 483 Observations at the Conclusion of a Drug cGMP Inspection, Docket No. FDA-2025-D-1504.
We supports FDA’s goal of promoting clear, organized, risk-based responses to FDA Form 483 observations. The attached comment letter requests additional clarification regarding response format flexibility, interim reporting expectations, electronic submission procedures, the 15-business-day response timeframe, consultant expectations, remediation closeout, FDA communication of inspection findings and post-response status, reinspection communication, pathways for resolving scientific or technical disagreements and applicability to 503A compounding facilities,.
Empower appreciates FDA’s consideration of these comments and welcomes continued engagement to support clarity, feasibility, and effective remediation of inspection observations.